Verve Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sekar Kathiresan
- Full Time Employees
- 274
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 Technology Square Boston MA United States of America 02139
- IPO Date
- Jun 17, 2021
- CIK
- 0001840574
- Website
- vervetx.com
- Similar Companies
- Business
- Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage biotechnology company developing single-course in vivo gene editing medicines targeting the root causes of atherosclerotic cardiovascular disease (ASCVD) through base editing technology to permanently inactivate disease-driving genes in the liver; its lead programs include VERVE-102, which targets the PCSK9 gene to durably reduce low-density lipoprotein cholesterol (LDL-C) for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease patients, VERVE-201, which targets the ANGPTL3 gene to lower LDL-C and triglycerides for refractory hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH), and VERVE-301, which targets the LPA gene to reduce lipoprotein(a) levels in ASCVD patients with high Lp(a). Founded in 2018 and headquartered in Boston, Massachusetts, the company operates primarily in the United States with a global focus on cardiovascular disease affecting hundreds of millions worldwide, advancing its pipeline through Phase 1b clinical trials such as Heart-2 for VERVE-102, where dosing in multiple cohorts has shown good tolerability as of early 2025, and Pulse-1 for VERVE-201. Recent developments include Eli Lilly and Company's agreement announced in late 2025 to acquire Verve for up to $1.3 billion to accelerate its gene editing programs, nomination of VERVE-301 as a development candidate in January 2025 with a related milestone payment from Lilly, progression of Heart-2 initial data expected in Q2 2025, and regaining rights to an undisclosed in vivo gene editing program for liver disease following termination of a Vertex Pharmaceuticals collaboration.
Three Biotechs That Are Top Takeover Targets
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Lilly and Verve announce expiration of Verve tender offer
3 Bullish Biotech Stocks With Explosive Growth Trends
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
Why Verve Therapeutics Stock Is Skyrocketing Today
Biotech Stock Surging on Billion-Dollar Buyout
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.
Eli Lilly lining up $1.3bn swoop for cholesterol specialist Verve
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports